These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26328030)

  • 1. Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection.
    Naqvi A; Giordanengo V; Dunais B; de Salvador-Guillouet F; Perbost I; Durant J; Pugliese P; Joulié A; Roger PM; Rosenthal E
    World J Hepatol; 2015 Aug; 7(18):2177-83. PubMed ID: 26328030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
    Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC
    J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
    Miailhes P; Gilbert C; Lacombe K; Arends JE; Puoti M; Rockstroh JK; Sogni P; Fontaine H; Rosenthal E; Winnock M; Loko MA; Wittkop L; Dabis F; Salmon D;
    Liver Int; 2015 Sep; 35(9):2090-9. PubMed ID: 25650873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
    Rosenthal E; Fougerou-Leurent C; Renault A; Carrieri MP; Marcellin F; Garraffo R; Teicher E; Aumaitre H; Lacombe K; Bailly F; Billaud E; Chevaliez S; Dominguez S; Valantin MA; Reynes J; Naqvi A; Cotte L; Metivier S; Leroy V; Dupon M; Allegre T; De Truchis P; Jeantils V; Chas J; Salmon-Ceron D; Morlat P; Neau D; Perré P; Piroth L; Pol S; Bourlière M; Pageaux GP; Alric L; Zucman D; Girard PM; Poizot-Martin I; Yazdanpanah Y; Raffi F; Pabic EL; Tual C; Pailhé A; Amri I; Bellissant E; Molina JM;
    HIV Med; 2018 Mar; 19(3):227-237. PubMed ID: 29214737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients.
    Arends JE; van der Meer JT; Posthouwer D; Kortmann W; Brinkman K; van Assen S; Smit C; van der Valk M; van der Ende M; Schinkel J; Reiss P; Richter C; Hoepelman AI; ;
    Neth J Med; 2015 Aug; 73(7):324-30. PubMed ID: 26314715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral therapies for chronic hepatitis C virus infection with cirrhosis.
    Nakamoto S; Kanda T; Shirasawa H; Yokosuka O
    World J Hepatol; 2015 May; 7(8):1133-41. PubMed ID: 26052402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
    Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
    J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ; Lancaster JW
    Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.
    Naik GS; Tyagi MG
    J Clin Exp Hepatol; 2012 Mar; 2(1):42-54. PubMed ID: 25755405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
    Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
    Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.
    Beste LA; Green PK; Ioannou GN
    Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
    Braun DL; Rauch A; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Metzner KJ; Böni J; Weber R; Fehr J
    HIV Med; 2014 Nov; 15(10):625-30. PubMed ID: 24894776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection.
    Jiménez-Sousa MA; Berenguer J; Rallón N; Pineda-Tenor D; Aldamiz-Echevarria T; Soriano V; García-Álvarez M; Vazquez-Morón S; Restrepo C; Carrero A; Benito JM; Resino S
    Liver Int; 2016 Sep; 36(9):1258-66. PubMed ID: 26836972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients.
    Bonnet D; Guivarch M; Bérard E; Combis JM; Remy AJ; Glibert A; Payen JL; Metivier S; Barange K; Desmorat H; Palacin A; Nicot F; Abravanel F; Alric L
    World J Hepatol; 2014 Sep; 6(9):660-9. PubMed ID: 25276282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.